combination of Ivabradine and bisoprolol — Competitive Intelligence Brief

combination of Ivabradine and bisoprolol (combination of Ivabradine and bisoprolol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiarrhythmic. Area: Cardiovascular.

phase 3 Antiarrhythmic I(f) channel Cardiovascular Small molecule

Target snapshot

combination of Ivabradine and bisoprolol (combination of Ivabradine and bisoprolol) — Ain Shams University. Ivabradine works by inhibiting the I(f) channel in the sinoatrial node, reducing heart rate, while bisoprolol acts as a beta-1 selective adrenergic receptor blocker, further reducing heart rate and contractility.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
combination of Ivabradine and bisoprolol TARGET	combination of Ivabradine and bisoprolol	Ain Shams University	phase 3	Antiarrhythmic	I(f) channel
Ivabradine and Metoprolol	Ivabradine and Metoprolol	Col. Suthee Panichkul	marketed	Combination: If channel inhibitor and beta-1 adrenergic antagonist	If channel (HCN4) and beta-1 adrenergic receptor
Multaq	DRONEDARONE	Sanofi	marketed	Antiarrhythmic [EPC]	Potassium voltage-gated channel subfamily KQT member 2	2009-01-01
Tikosyn	DOFETILIDE	Pfizer	marketed	Antiarrhythmic [EPC]	Potassium voltage-gated channel subfamily H member 2	1999-01-01
Corvert	IBUTILIDE	Pfizer	marketed	Antiarrhythmic	Potassium voltage-gated channel subfamily H member 2	1995-01-01
Tambocor	FLECAINIDE		marketed	Antiarrhythmic	Potassium voltage-gated channel subfamily H member 2	1985-01-01
Cordarone	AMIODARONE	Pfizer	marketed	Antiarrhythmic	sodium channels, potassium channels, calcium channels	1985-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiarrhythmic class)

1. Pfizer · 3 drugs in this class
2. National Taiwan University Hospital · 2 drugs in this class
3. Boehringer Ingelheim · 1 drug in this class
4. Cliniques universitaires Saint-Luc- Université Catholique de Louvain · 1 drug in this class
5. Eli Lilly · 1 drug in this class
6. MTI Medical Private Limited, Pakistan · 1 drug in this class
7. Technical University of Munich · 1 drug in this class
8. · 1 drug in this class
9. Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class
10. Ain Shams University · 1 drug in this class